Abnova — Investor Presentation 2021

Nov 1, 2021

==> picture [129 x 42] intentionally omitted <==

Abnova (Taiwan) Corp. (4133.TW) 2021 Investor Conference

Innovate through Integrated Solutions

2021/11/3

==> picture [751 x 70] intentionally omitted <==

==> picture [56 x 55] intentionally omitted <==

==> picture [77 x 153] intentionally omitted <==

Safe Harbor Notice

The following pages contain projections & estimates of financial information as well as market and product developments for future periods. These projections & estimates are based on information currently available which we believe to be reliable, but they involve risks & uncertainties. Our actual results of operations & financial condition may differ significantly from those contained in the projections & estimates. The projections & estimates should not be interpreted as legally binding commitments, but rather as flexible information subject to change occasionally.

2

2

==> picture [77 x 153] intentionally omitted <==

Our Agenda



Abnova Company Profile About us ‐ Our history and archives



Abnova Q2&H1‐2021 Financial Results Q2&H1‐2021 financial results, revenue by product



Abnova Product Family The latest product development progress in 2021

==> picture [112 x 33] intentionally omitted <==

3



Abnova Company Profile

4

4

Abnova Company Profile

==> picture [451 x 228] intentionally omitted <==

==> picture [331 x 188] intentionally omitted <==

==> picture [331 x 188] intentionally omitted <==

==> picture [451 x 227] intentionally omitted <==

5

5

==> picture [525 x 162] intentionally omitted <==

==> picture [193 x 171] intentionally omitted <==

==> picture [525 x 162] intentionally omitted <==

==> picture [194 x 146] intentionally omitted <==

==> picture [294 x 189] intentionally omitted <==

==> picture [427 x 189] intentionally omitted <==

6

6

==> picture [582 x 532] intentionally omitted <==

7

7

==> picture [595 x 348] intentionally omitted <==

==> picture [595 x 174] intentionally omitted <==

8

8



==> picture [32 x 46] intentionally omitted <==

Abnova Q2&H1‐2021 Financial Results

9

9

Consolidated Income Statement Q2&H1 2021

	Q2‘21	%	Q2‘20	%	H1‘21	%	H1‘20	%	H1 YOY
Net Revenue	124,254	100.00%	103,319	100%	238,582	100.00%	203,229	100.00%	17.40%
Cost of Revenue	‐70,557	‐56.78%	‐56,609	‐54.79%	‐133,377	‐55.90%	‐110,523	‐54.38%	20.68%
Gross Profit	53,697	43.22%	46,710	45.21%	105,205	44.10%	92,706	45.62%	13.48%
Operating Expense	‐39,677	‐31.93%	‐38,309	‐37.08%	‐79,203	‐33.20%	‐77,020	‐37.90%	2.83%
Operating Income	14,020	11.28%	8,401	8.13%	26,002	9.90%	15,686	7.72%	‐65.77%
Non Operating Income	‐4,503	‐3.62%	‐3,009	‐2.91%	‐4,282	‐2.79%	‐900	‐0.44%	375.78%
Income before Tax	9,517	7.66%	5,392	5.22%	21,720	8.10%	14,786	7.28%	‐46.90%
Income after Tax	6,917	5.57%	4,122	3.99%	16,679	5.99%	11,818	5.82%	41.13%
Basic EPS after Tax	0.11		0.07		0.28		0.2

10

10

Revenue Breakdown by Product

==> picture [718 x 291] intentionally omitted <==

==> picture [718 x 146] intentionally omitted <==

11



Abnova Product Family

12

12

Abnova Product Family

COVID‐19 Delta Variant Neutralizing Antibody ELISA Kit

COVID‐19 Delta Variant Pseudovirus Neutralizing Antibody Assay

COVID‐19 Neutralizing Antibody Rapid Test

COVID‐19 SAM Universal Vaccine

Prostate Cancer SAM Vaccine

CytoQuest™ CR

attIL‐12 Cell Therapy

13

13

COVID‐19 Delta Variant Neutralizing Antibody ELISA Kit

COVID-19 Delta Variant Neutralizing Antibody ELISA Kit

==> picture [334 x 202] intentionally omitted <==

==> picture [309 x 219] intentionally omitted <==

14

14

COVID‐19 Delta Variant Pseudovirus Neutralizing Antibody Assay

COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay

==> picture [710 x 215] intentionally omitted <==

15

COVID‐19 Delta Variant Pseudovirus Neutralizing Antibody Assay

COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay

==> picture [614 x 26] intentionally omitted <==

==> picture [613 x 73] intentionally omitted <==

==> picture [454 x 144] intentionally omitted <==

16

16

COVID‐19 Neutralizing Antibody Rapid Test To monitor the titer of neutralizing antibodies after vaccination

==> picture [405 x 113] intentionally omitted <==

==> picture [345 x 179] intentionally omitted <==

==> picture [418 x 113] intentionally omitted <==

==> picture [298 x 393] intentionally omitted <==

17

17

COVID‐19 SAM Universal Vaccine

==> picture [708 x 137] intentionally omitted <==

==> picture [751 x 128] intentionally omitted <==

==> picture [751 x 129] intentionally omitted <==

18

18

COVID‐19 SAM Universal Vaccine

==> picture [339 x 307] intentionally omitted <==

==> picture [426 x 154] intentionally omitted <==

==> picture [426 x 154] intentionally omitted <==

19

19

COVID‐19 SAM Universal Vaccine

==> picture [531 x 121] intentionally omitted <==

==> picture [531 x 121] intentionally omitted <==

==> picture [529 x 209] intentionally omitted <==

20

20

COVID‐19 SAM Universal Vaccine

==> picture [396 x 412] intentionally omitted <==

==> picture [398 x 264] intentionally omitted <==

21

21

COVID‐19 SAM Universal Vaccine

==> picture [394 x 428] intentionally omitted <==

==> picture [397 x 250] intentionally omitted <==

22

22

COVID‐19 SAM Universal Vaccine

==> picture [487 x 163] intentionally omitted <==

==> picture [487 x 24] intentionally omitted <==

==> picture [399 x 100] intentionally omitted <==

==> picture [399 x 181] intentionally omitted <==

==> picture [338 x 16] intentionally omitted <==

==> picture [370 x 216] intentionally omitted <==

23

COVID‐19 SAM Universal Vaccine

==> picture [478 x 20] intentionally omitted <==

==> picture [375 x 169] intentionally omitted <==

==> picture [375 x 170] intentionally omitted <==

==> picture [372 x 168] intentionally omitted <==

==> picture [372 x 168] intentionally omitted <==

==> picture [568 x 47] intentionally omitted <==

==> picture [601 x 36] intentionally omitted <==

24

24

Prostate Cancer SAM Vaccine

in vitro models

in vivo models

==> picture [519 x 124] intentionally omitted <==

25

CytoQuest™ CR

Class III CFDA Approval

==> picture [492 x 308] intentionally omitted <==

==> picture [268 x 218] intentionally omitted <==

==> picture [185 x 167] intentionally omitted <==

==> picture [561 x 77] intentionally omitted <==

==> picture [112 x 33] intentionally omitted <==

26

attIL‐12 Cell Therapy

Bladder Cancer PDX Model

==> picture [773 x 228] intentionally omitted <==

==> picture [773 x 115] intentionally omitted <==

27

27

==> picture [131 x 189] intentionally omitted <==

Thank You

Abnova Innovate through Integrated Solutions

==> picture [751 x 70] intentionally omitted <==

==> picture [56 x 55] intentionally omitted <==